Affinage

CLDN6

Claudin-6 · UniProt P56747

Length
220 aa
Mass
23.3 kDa
Annotated
2026-04-28
43 papers in source corpus 21 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CLDN6 is a four-pass transmembrane tight junction protein that functions as a signaling scaffold, coupling cell-cell adhesion to diverse intracellular pathways that control proliferation, autophagy, apoptosis, metabolic reprogramming, and differentiation. Its C-terminal cytoplasmic tail domain, which contains a PDZ-binding motif, is essential for membrane targeting and mediates direct interactions with signaling partners including LKB1 (AMPK/ULK1 autophagy), JNK (c-Jun/WIP-actin-autophagy), ZO-1/PTEN (AKT/MDM2-p53 stabilization), MAGI2 (KLF5/SREBP1-RAS palmitoylation), LATS1/2 and TAZ (Hippo-YAP signaling), RIP1 (ASK1/JNK axis), BLK/SRC (epithelial differentiation), and afadin (ERK suppression) (PMID:16847338, PMID:36935496, PMID:37852424, PMID:39169280, PMID:31827075, PMID:35008557, PMID:37443730, PMID:29159771, PMID:40959289). CLDN6 expression is epigenetically silenced by DNMT1-mediated promoter methylation downstream of TGFβ/SMAD2 signaling and transcriptionally activated by ERβ and HIF-1α, with HIF-1α and CLDN6 forming a negative feedback loop through β-catenin sequestration and SENP1-dependent HIF-1α SUMOylation and degradation (PMID:28867761, PMID:31412908, PMID:32093760, PMID:19288010). In vivo, CLDN6 overexpression in mouse epidermis perturbs epidermal permeability barrier formation and hair follicle differentiation, while its tail-deletion mutant causes mislocalization of multiple claudins and activates a protein-unfolding response (PMID:15908185, PMID:16847338).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2005 High

    Establishing CLDN6 as a functional regulator of epidermal barrier formation and differentiation in vivo, rather than merely a structural tight junction component, by showing that its transgenic overexpression perturbs barrier formation and hair follicle morphogenesis.

    Evidence Inv-Cldn6 transgenic mouse model with histological, immunofluorescence, and western blot analysis

    PMID:15908185

    Open questions at the time
    • Mechanism by which CLDN6 overexpression alters claudin compartmentalization not defined
    • Endogenous loss-of-function model not tested
  2. 2006 High

    Demonstrating that the cytoplasmic tail domain is required for CLDN6 membrane targeting and normal function, as its deletion causes mislocalization of CLDN6 and other claudins, activates an unfolded protein response, and disrupts epidermal differentiation — establishing the tail as the key signaling and trafficking domain.

    Evidence Structure-function transgenic mouse model with Inv promoter-driven tail-deletion mutant (CΔ187)

    PMID:16847338

    Open questions at the time
    • Specific tail residues or motifs responsible for trafficking not mapped
    • Whether the UPR activation is a direct or indirect consequence of mislocalization unclear
  3. 2009 Medium

    Revealing that CLDN6 silencing in cancer is driven by promoter DNA methylation, as demethylation with 5-aza-dC restored expression — establishing epigenetic regulation as a key mechanism of CLDN6 loss in tumors.

    Evidence Methylation-specific analysis and pharmacological demethylation in esophageal squamous cell carcinoma

    PMID:19288010

    Open questions at the time
    • Specific methyltransferase responsible not identified in this study
    • Functional consequence of CLDN6 re-expression not tested
  4. 2016 Medium

    Linking CLDN6 to apoptotic signaling by showing it activates the ASK1-JNK/p38-caspase-3 cascade, shifting the Bcl-2/Bax ratio — the first demonstration of CLDN6 engaging a kinase-mediated death pathway in cancer cells.

    Evidence Stable transfection in MCF-7 breast cancer cells with ASK1 inhibitor (TRX1) rescue, TUNEL, DNA ladder, and colony formation assays

    PMID:27035750

    Open questions at the time
    • Direct physical interaction between CLDN6 and ASK1 not shown
    • Mechanism of ASK1 Ser967 dephosphorylation by CLDN6 not defined
  5. 2017 Medium

    Identifying the TGFβ/SMAD2-DNMT1 axis as the upstream mechanism for CLDN6 promoter methylation and defining CLDN6's interactions with p53 (promoting cytoplasmic translocation and GSTP1-dependent chemoresistance) and afadin (suppressing ERK signaling), establishing CLDN6 as a multi-pathway signaling hub.

    Evidence ChIP assays for DNMT1 binding to CLDN6 promoter; Co-IP for CLDN6-p53 and CLDN6-afadin interactions; pharmacological rescue experiments in breast cancer cells

    PMID:28867761 PMID:29116019 PMID:29159771

    Open questions at the time
    • CLDN6-p53 interaction mechanism (direct vs. bridged) not resolved
    • Whether afadin interaction requires the PDZ-binding motif not tested
    • Chemoresistance findings from single lab
  6. 2019 High

    Connecting CLDN6 to the Hippo pathway through direct interaction with LATS1/2 (reducing YAP1 phosphorylation and promoting its nuclear entry for EMT) and to ERβ-driven autophagy (beclin1-dependent) as a metastasis suppressor, revealing context-dependent opposing roles.

    Evidence Co-IP for CLDN6-LATS1/2 in gastric cancer; ChIP and reporter assays for ERβ binding to CLDN6 promoter plus in vivo xenograft in breast cancer

    PMID:31412908 PMID:31827075

    Open questions at the time
    • Opposing roles (pro-EMT in gastric vs. anti-metastasis in breast cancer) not mechanistically reconciled
    • Whether CLDN6-LATS interaction is direct or scaffolded not determined
  7. 2020 High

    Establishing a HIF-1α–CLDN6 negative feedback loop: HIF-1α transcriptionally activates CLDN6, which sequesters β-catenin in the cytoplasm to reduce SENP1, causing HIF-1α SUMOylation and degradation — revealing CLDN6 as an oxygen-sensing circuit component that suppresses metastasis.

    Evidence ChIP, Co-IP, mRNA-seq/KEGG, RNAi rescue, migration/invasion assays, and clinical sample validation in breast cancer

    PMID:32093760

    Open questions at the time
    • Direct CLDN6–β-catenin binding not confirmed
    • Generalizability beyond breast cancer not tested
  8. 2021 Medium

    Demonstrating that CLDN6 forms a complex with TJP2 and YAP1 to activate Hippo signaling in hepatocellular carcinoma, driving hepatic-to-biliary lineage plasticity — extending CLDN6's Hippo pathway role to lineage determination.

    Evidence Co-IP, overexpression/knockdown functional assays in HCC cells

    PMID:33536280

    Open questions at the time
    • Whether TJP2 bridges CLDN6 to YAP1 or all three interact simultaneously not resolved
    • In vivo lineage tracing not performed
  9. 2022 Medium

    Expanding CLDN6's metabolic and proliferative control by showing it interacts with TAZ to suppress c-MYC transcription and aerobic glycolysis, and independently suppresses ERK/Sp1/cyclin D1 and ERK/IL-8/CXCR2/FAK cascades to inhibit proliferation and invasion in breast cancer.

    Evidence Metabolomic analysis, Co-IP for CLDN6-TAZ; pharmacological ERK activation (PMA) rescue experiments

    PMID:35008557 PMID:35752352

    Open questions at the time
    • Direct binding site on TAZ not mapped
    • ERK suppression mechanism (direct vs. indirect through afadin or other scaffold) not clarified
  10. 2023 High

    Identifying BLK and SRC as direct binding partners of CLDN6's cytoplasmic tail (phosphotyrosine-independent) essential for epithelial differentiation, and defining the ZO-1/PTEN-AKT/MDM2 axis through which CLDN6 stabilizes p53 to inhibit colorectal cancer proliferation.

    Evidence Recombinant protein pull-down and CRISPR/Cas9 knockout of Blk/Src in F9 cells; Co-IP and ubiquitination assays for ZO-1/PTEN/p53 axis in CRC cells

    PMID:37443730 PMID:37852424

    Open questions at the time
    • Structural basis of Src-family kinase binding to CLDN6 tail not determined
    • Whether ZO-1 interaction is PDZ-dependent was assumed but not mutationally confirmed
  11. 2024 High

    Revealing CLDN6's role in controlling RAS oncogenic signaling through MAGI2/KLF5/SREBP1-dependent de novo palmitate synthesis and RAS palmitoylation, and identifying RIP1 as another PDZ-dependent partner linking CLDN6 to glycolysis suppression via ASK1/JNK in NSCLC.

    Evidence Co-IP, ChIP, acyl-biotin exchange palmitoylation assay, in vivo xenograft/metastasis models for MAGI2 axis; Co-IP and Seahorse assay for RIP1 axis

    PMID:38462752 PMID:39169280

    Open questions at the time
    • Whether CLDN6-MAGI2 complex directly sequesters KLF5 or acts indirectly not fully resolved
    • RIP1 interaction not confirmed by reciprocal or recombinant methods
  12. 2025 Medium

    Extending CLDN6's signaling repertoire to ferroptosis regulation (via DLG1/PBK complex recruitment, PBK proteasomal degradation, and NRF2 nuclear export) and to chemoresistance via LKB1/AMPK/ULK1-dependent protective autophagy induced by ROS/GATA4 signaling.

    Evidence Co-IP, UPS inhibitor experiments, ferroptosis assays; Co-IP, autophagy and ROS assays for LKB1 pathway

    PMID:39984471 PMID:40959289

    Open questions at the time
    • DLG1-mediated PBK degradation E3 ligase not identified
    • Whether LKB1 interaction is direct or scaffolded not confirmed with recombinant proteins
    • Single-lab findings for both pathways

Open questions

Synthesis pass · forward-looking unresolved questions
  • A structural model of CLDN6's cytoplasmic tail and its PDZ-binding motif in complex with its numerous partners is lacking, and the rules governing which signaling pathway is engaged in a given cellular context remain undefined.
  • No crystal or cryo-EM structure of CLDN6 cytoplasmic domain with any partner
  • Context-dependent pathway selection mechanism unknown
  • No endogenous knockout mouse model characterizing CLDN6 loss-of-function systemically

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 11 GO:0005198 structural molecule activity 2 GO:0008092 cytoskeletal protein binding 1
Localization
GO:0005886 plasma membrane 5
Pathway
R-HSA-162582 Signal Transduction 13 R-HSA-1430728 Metabolism 3 R-HSA-9612973 Autophagy 3 R-HSA-1266738 Developmental Biology 2 R-HSA-1500931 Cell-Cell communication 2 R-HSA-4839726 Chromatin organization 2 R-HSA-5357801 Programmed Cell Death 2
Partners
AFDNBLKLATS1MAGI2RIPK1SRCTJP2YAP1

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 CLDN6 interacts with LATS1/2 in the Hippo signaling pathway, reducing phosphorylation of LATS1/2 and YAP1, thereby promoting nuclear entry of YAP1, which then interacts with Snail1 to drive EMT and enhance invasion in gastric cancer cells. Co-immunoprecipitation, western blot, in vitro/in vivo functional assays Cell death & disease Medium 31827075
2021 CLDN6 interacts with TJP2 (tight junction protein 2) and YAP1 (Yes-associated protein 1) to activate Hippo signaling, inducing phenotypic shift of HCC cells from hepatic to biliary lineage and enhancing lineage plasticity. Co-immunoprecipitation, overexpression/knockdown functional assays, western blot Science translational medicine Medium 33536280
2019 ERβ transcriptionally upregulates CLDN6 by binding directly to the CLDN6 promoter, and CLDN6 inhibits breast cancer migration and invasion by positively regulating beclin1-dependent autophagy; beclin1 knockdown reverses the CLDN6-mediated inhibition of metastasis. ChIP assay, dual luciferase reporter assay, wound healing/Transwell assays, western blot, immunofluorescence, TEM, xenograft mouse models Journal of experimental & clinical cancer research : CR High 31412908
2016 CLDN6 restoration in MCF-7 breast cancer cells decreases ASK1 phosphorylation at Ser967, activating downstream JNK and p38 kinases, leading to altered Bcl-2/Bax ratio and caspase-3 cleavage to induce apoptosis; inhibition of ASK1 with TRX1 reverses these effects. Stable transfection, ASK1 inhibitor (TRX1) treatment, western blot, TUNEL staining, DNA ladder, colony formation assay International journal of oncology Medium 27035750
2017 CLDN6 promotes chemoresistance in breast cancer by interacting with p53 and promoting its translocation from nucleus to cytoplasm, thereby upregulating GSTP1 expression and enzyme activity; silencing GSTP1 abolishes CLDN6-mediated chemoresistance. Co-immunoprecipitation, RNAi knockdown, GST activity assay, CCK-8 cytotoxicity assay, western blot Journal of experimental & clinical cancer research : CR Medium 29116019
2017 CLDN6 colocalizes and interacts with afadin (AF-6), increasing AF-6 expression and inhibiting ERK signaling activation; ERK activator (PMA) reverses CLDN6-mediated chemoresistance and cancer stem cell marker upregulation in TNBC cells. Co-immunoprecipitation, immunofluorescence, PMA treatment (ERK activator), western blot Molecular and cellular biochemistry Medium 29159771
2017 SMAD2 pathway (TGFβ signaling) regulates CLDN6 promoter methylation through DNMT1; inhibition of SMAD2 with SB431542 reduces DNMT1 expression and its binding to the CLDN6 promoter, decreasing methylation and increasing CLDN6 protein expression, which inhibits EMT, migration and invasion in breast cancer cells. ChIP assay, methylation-specific PCR, DNMT1 knockdown, western blot, Transwell assay International journal of molecular sciences Medium 28867761
2006 The cytoplasmic tail domain of CLDN6 is required for proper membrane targeting; a tail-deletion mutant (CDelta187) mislocalizes CLDN6 and other claudins (CLDN10, CLDN11, CLDN18) to the cytoplasm, activates a protein-unfolding pathway, and causes aberrant epidermal differentiation and increased proliferation in transgenic mouse epidermis. Structure-function transgenic mouse model (Inv promoter-driven tail deletion), immunofluorescence/immunohistochemistry, western blot Molecular and cellular biology High 16847338
2005 Overexpression of CLDN6 in mouse epidermis (Inv-Cldn6 transgenic) perturbs epidermal differentiation, delays epidermal permeability barrier formation, alters claudin expression compartments (inducing CLDN5 and CLDN8), and disrupts hair follicle differentiation including shortened anagen phase and altered hair type distribution. Transgenic mouse model, histological analysis, immunofluorescence, western blot Mechanisms of development High 15908185
2020 HIF-1α transcriptionally upregulates CLDN6 under hypoxia; CLDN6 in turn sequesters β-catenin in the cytoplasm (preventing nuclear translocation), reducing SENP1 expression, preventing deSUMOylation of HIF-1α, and leading to HIF-1α degradation — establishing a negative feedback loop that suppresses breast cancer metastasis. RNAi, ChIP assay, mRNA-seq/KEGG analysis, co-immunoprecipitation, functional migration/invasion assays, clinical sample validation Journal of experimental & clinical cancer research : CR High 32093760
2022 CLDN6 interacts with TAZ (a transcriptional co-activator with PDZ-binding motif) and reduces TAZ levels, thereby suppressing c-MYC transcription, leading to reduced glucose uptake and lactate production and inhibiting aerobic glycolysis-dependent proliferation in breast cancer. Metabolomic analysis, co-immunoprecipitation, western blot, in vitro and in vivo proliferation assays International journal of molecular sciences Medium 35008557
2023 CLDN6 interacts with JNK via its PDZ-binding motif, upregulating the JNK/c-Jun pathway; c-Jun transcriptionally promotes WIP expression, which mediates actin cytoskeleton assembly driving autophagy and inhibiting breast cancer metastasis. A positive feedback loop exists between CLDN6 and JNK/c-Jun. Co-immunoprecipitation, ChIP assay, dual luciferase reporter assay, immunofluorescence, phalloidin staining, mRNA-seq, western blot, in vivo lung metastasis models Journal of experimental & clinical cancer research : CR High 36935496
2022 CLDN6 suppresses ERK/Sp1/cyclin D1 signaling to inhibit breast cancer cell proliferation and suppresses ERK/IL-8 signaling (via CXCR2/FAK) to inhibit migration and invasion; ERK activator PMA reverses these inhibitory effects. Overexpression constructs, ERK activator (PMA) treatment, western blot, migration/invasion assays Cellular signalling Medium 35752352
2023 CLDN6 binds to ZO-1 via its PDZ-binding motif, interacts with PTEN, and regulates the AKT/MDM2 pathway to reduce MDM2-mediated ubiquitination of p53, enhancing p53 stability and nuclear import, thereby inhibiting colorectal cancer cell proliferation. Co-immunoprecipitation, western blot, ubiquitination assay, nuclear fractionation, in vitro and in vivo proliferation assays Cellular signalling Medium 37852424
2023 BLK and SRC (Src-family kinases) directly bind to the C-terminal cytoplasmic domain of CLDN6 (independent of phosphotyrosine status) and are essential for CLDN6-triggered epithelial differentiation and expression of retinoic acid receptor target genes in F9 cells. Immunoprecipitation, pull-down assay with recombinant proteins, CRISPR/Cas9 knockout of Blk and Src in F9:Cldn6 cells, phenotypic comparison Cells High 37443730
2024 CLDN6 interacts with MAGI2 via its PDZ-binding motif, preventing KLF5 nuclear translocation and restraining SREBF1 transcription; reduced SREBP1 decreases de novo palmitic acid synthesis, thereby inhibiting RAS palmitoylation and ESCRT-mediated RAS plasma membrane localization required for RAS oncogenic activation, suppressing breast cancer growth and metastasis. Co-immunoprecipitation, nuclear fractionation, ChIP assay, dual luciferase reporter assay, acyl-biotin exchange (IP-ABE) assay, western blot, xenograft and lung metastasis mouse models, tissue microarray Cellular & molecular biology letters High 39169280
2024 CLDN6 interacts with RIP1 (receptor interacting protein 1) via co-immunoprecipitation and inhibits aerobic glycolysis and cell proliferation in NSCLC through the RIP1/ASK1/JNK axis; CLDN6 expression is silenced by DNA methylation in NSCLC. Co-immunoprecipitation, methylation-specific PCR, western blot, Seahorse assay, in vivo xenograft Journal of biochemical and molecular toxicology Medium 38462752
2025 CLDN6 triggers NRF2-mediated ferroptosis in breast cancer by recruiting DLG1/PBK complex to the cell membrane via the endosomal pathway, promoting PBK degradation through the ubiquitin-proteasome system (UPS), and thereby regulating the PBK-dependent AKT/GSK3β/FYN axis to enhance NRF2 nuclear export. Co-immunoprecipitation, immunofluorescence, western blot, in vitro and in vivo ferroptosis assays, UPS inhibitor experiments Cell death & disease Medium 39984471
2025 CLDN6 interacts with LKB1 through its PDZ-binding motif, activating AMPK/ULK1 signaling to induce protective autophagy and promote chemoresistance in breast cancer; chemotherapy increases CLDN6 expression through the ROS/GATA4 axis. Co-immunoprecipitation, western blot, autophagy assays, ROS measurement, cell viability assays International journal of biological sciences Medium 40959289
2025 CLDN6 is identified as a defining surface marker of columnar trophoblast cells that bridge villous and extravillous compartments in the human chorion; prospective isolation of living CLDN6+ trophoblast confirmed their dual developmental potential to reacquire a proliferative villous state and generate both syncytial and extravillous fates under directed cues. Single-cell transcriptomics, HIPPO pathway modulation (LATS kinase inhibition), prospective cell isolation, 3D organoid culture, lineage differentiation assays bioRxiv (preprint)preprint Medium bio_10.1101_2025.11.18.688276
2009 CLDN6 is silenced by promoter DNA methylation in esophageal squamous cell carcinoma; treatment with the demethylating agent 5-aza-2'-deoxycytidine (aza-dC) reduces methylation and restores CLDN6 mRNA expression, demonstrating epigenetic regulation of CLDN6. Methylation analysis, 5-aza-2'-deoxycytidine demethylation treatment, RT-PCR Oncology reports Medium 19288010

Source papers

Stage 0 corpus · 43 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2023 CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nature medicine 208 37872225
2019 Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. Journal of experimental & clinical cancer research : CR 117 31412908
2019 CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer. Cell death & disease 73 31827075
2021 Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Science translational medicine 59 33536280
2017 CLDN6 promotes chemoresistance through GSTP1 in human breast cancer. Journal of experimental & clinical cancer research : CR 59 29116019
2005 Delayed epidermal permeability barrier formation and hair follicle aberrations in Inv-Cldn6 mice. Mechanisms of development 54 15908185
2009 Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncology reports 49 19288010
2016 CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells. International journal of oncology 43 27035750
2006 Role of the Cldn6 cytoplasmic tail domain in membrane targeting and epidermal differentiation in vivo. Molecular and cellular biology 40 16847338
2020 A SUMOylation-dependent HIF-1α/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis. Journal of experimental & clinical cancer research : CR 39 32093760
2023 Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 37 36884217
2018 Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B. OncoTargets and therapy 33 30319275
2021 CLDN6: From Traditional Barrier Function to Emerging Roles in Cancers. International journal of molecular sciences 32 34948213
2017 CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231. Molecular and cellular biochemistry 31 29159771
2022 KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer. Life sciences 28 35051418
2017 SMAD2 Inactivation Inhibits CLDN6 Methylation to Suppress Migration and Invasion of Breast Cancer Cells. International journal of molecular sciences 27 28867761
2023 CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton-mediated autophagy. Journal of experimental & clinical cancer research : CR 26 36935496
2021 Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family. Frontiers in genetics 23 34249076
2020 Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR/AKT/mTOR signalling pathway in hepatocellular carcinoma. Cell biochemistry and function 21 32056244
2021 CLDN6 Suppresses c-MYC-Mediated Aerobic Glycolysis to Inhibit Proliferation by TAZ in Breast Cancer. International journal of molecular sciences 20 35008557
2024 CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation. Cellular & molecular biology letters 19 39169280
2021 The Expression of CLDN6 in Hepatocellular Carcinoma Tissue and the Effects of CLDN6 on Biological Phenotypes of Hepatocellular Carcinoma Cells. Journal of Cancer 17 34405008
2022 CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling. Cellular signalling 15 35752352
2023 Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options. Molecular medicine (Cambridge, Mass.) 14 36991316
2020 Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers. Pathology oncology research : POR 14 32170581
2024 SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137. Journal for immunotherapy of cancer 13 39401967
2021 Effects of the Tight Junction Protein CLDN6 on Cell Migration and Invasion in High-Grade Meningioma. World neurosurgery 9 33862296
2023 The Src-Family Kinases SRC and BLK Contribute to the CLDN6-Adhesion Signaling. Cells 7 37443730
2022 The expression and the tumor suppressor role of CLDN6 in colon cancer. Molecular and cellular biochemistry 7 35701678
2020 CLDN6-mediates SB431542 action through MMPs to regulate the invasion, migration, and EMT of breast cancer cells. International journal of clinical and experimental pathology 7 32782677
2023 Downregulation of CLDN6 inhibits cell migration and invasion and promotes apoptosis by regulation of the JAK2/STAT3 signaling pathway in hepatocellular carcinoma. Translational cancer research 5 37588735
2023 CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/PTEN axis. Cellular signalling 5 37852424
2025 CLDN6 triggers NRF2-mediated ferroptosis through recruiting DLG1/PBK complex in breast cancer. Cell death & disease 4 39984471
2024 CLDN6 inhibited cellular biological function of nonsmall cell lung cancer cells through suppressing aerobic glycolysis via the RIP1/ASK1/JNK axis. Journal of biochemical and molecular toxicology 4 38462752
2023 CLDN6 Suppresses Migration and Invasion of MCF-7 and SKBR-3 Breast Cancer Cells by Blocking the SMAD/Snail/MMP-2/9 Axis. Bulletin of experimental biology and medicine 4 37566248
2025 Inhibition of DLK1 regulates AT2 differentiation and alleviates established pulmonary fibrosis by upregulating TTF-1/CLDN6. Respiratory research 2 40380180
2025 CLDN6 induces chemoresistance through protective autophagy in breast cancer. International journal of biological sciences 2 40959289
2026 CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications 1 41628300
2026 Anti-cancer effects of carvacrol on NUF2, CASP3 and CLDN6 expression in T47D breast cancer cells. Naunyn-Schmiedeberg's archives of pharmacology 0 41569314
2026 Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma. mAbs 0 41804857
2026 Evaluating Claudin-6 and isochromosome 12p in the progression from germ cell neoplasia in situ to primary testicular germ cell tumor and post-chemotherapy teratoma: implications for CLDN6-targeted therapies. Therapeutic advances in medical oncology 0 41835342
2026 A novel CLDN6 nanobody-based bispecific T-cell engager delivered by self-amplifying RNA platform exhibits potent antitumor efficacy. Journal of nanobiotechnology 0 41882748
2026 The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors. Andrology 0 41923292